CASC19 and familial pancreatic carcinoma: Thus, pancreatic cancer cells with upregulated and downregulated CASC19 were treated with a proteasome inhibitor MG132 and it was found that PSPC1 protein expression remained stable in CASC19 depleted and control cancer cells and the expression level was higher in CASC19 overexpressing and vector control cells (Fig. 5J, Fig. 5K).